Biotech 2050 Podcast cover image

New vision for preventing & curing age-related diseases, James Peyer, Founder & CEO, Cambrian Bio

Biotech 2050 Podcast

00:00

Cambrian's Approach to Drug Development

Cambrian currently has 15 drugs in development, including eight candidates. One program is moving into a phase one B later this year that we haven't announced yet. We tend to take a slightly slower approach to the maximum possible speed of taking a tool compound and rushing that into humans. And so we get on board with these kind of in vivo validation of a mechanism.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app